A1ZN34:BVMF
Astrazeneca Plc Bdr
148,93 R$
0,00%
(0,00) 1D
22 սեպ, 17:08:00 GMT-3 · BRL
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for A1ZN34...
Open
144,05 R$
High
148,93 R$
Low
143,11 R$
Mkt. cap
195,90 մլրդ
Avg. vol.
537,00
Volume
11,00
52-wk high
190,40 R$
52-wk low
130,02 R$
Shares outstanding
1,55 մլրդ
No. of employees
96 հզր
Open
144,05 R$
High
148,93 R$
Low
143,11 R$
Mkt. cap
195,90 մլրդ
Avg. vol.
537,00
Volume
11,00
52-wk high
190,40 R$
52-wk low
130,02 R$
Shares outstanding
1,55 մլրդ
No. of employees
96 հզր
News stories
From web sources and news partners
TipRanks
·
1 ժամ առաջ
AstraZeneca wins EU nod for first triple-combination asthma inhaler
TipRanks
·
15 ժամ առաջ
AstraZeneca Targets Chinese Lupus Market With New Anifrolumab Study
www.marketscreener.com
·
17 ժամ առաջ
Europe Is Losing the Pharma Investment Race – But the Comeback Is Within Reach: An open letter from the Chairs of AstraZeneca, Boehringer Ingelheim, Chiesi Group, Ipsen, GSK, Novo, Novartis, Roche, and Sanofi
Traders Union
·
1 օր առաջ
CHMP positive opinion for Enhertu: Can AstraZeneca stock test GBX13,620 resistance?
Profile
AstraZeneca plc is a Swedish–British multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.
The company was founded in 1999 through the merger of the Swedish Astra AB and the British Zeneca Group. Zeneca shareholders received 53.5% of the shares, while Astra shareholders received the remaining 46.5%. Its portfolio includes primary and speciality care, coverage for rare diseases, and a robust global presence across various regions. Since the merger it has been among the world's largest pharmaceutical companies and has made numerous corporate acquisitions, including Cambridge Antibody Technology, MedImmune, Spirogen and Definiens. It has its research and development concentrated in three strategic centres: Cambridge, England; Gothenburg, Sweden; and Gaithersburg, Maryland, US.
AstraZeneca traces its earliest corporate history to 1913, when Astra AB was formed by a large group of doctors and apothecaries in Södertälje. Wikipedia
About Astrazeneca Plc Bdr
CEOPascal Soriot
Employees96,1 հզր
Founded06 ապր, 1999 թ.
HeadquartersՔեմբրիջ, Cambridgeshire, Միացյալ Թագավորություն
Sector-
Websiteastrazeneca.com